View Document Preview and Link Document Date: 2014-10-01 21:51:53 Open Document File Size: 509,83 KB Share Result on Facebook
Company Kidney Health Australia / Alexion / aHUS Patient Support Group / / Holiday Commonwealth Day / / IndustryTerm treatment of atypical haemolytic uraemic syndrome / pharmaceutical / / MedicalCondition meningococcal infections / chronic dialysis / disease / serious meningococcal infections / thrombocytopenia / septicaemia / chronic kidney disease / atypical haemolytic uraemic syndrome / renal disease / infection / end stage renal disease / severe pulmonary impairment / renal failure / Severe cardiomyopathy / meningitis / recurrent disease / pulmonary impairment / / MedicalTreatment plasma exchange / renal transplantation / kidney transplant / antibiotics / vaccination / kidney transplantation / dialysis / / Organization Pharmaceutical Benefits Advisory Committee / Department of Human Services / Haematology Society of Australia and New Zealand / Therapeutic Goods Administration / Australian and New Zealand Paediatric Nephrology Association / Department of Health / MEDICARE / / / Product Soliris / / Technology transplantation / dialysis / / SocialTag 
Stakeholder meeting statement Pharmaceutical Benefits Scheme listing of eculizumab (Soliris®) for atypical haemolytic uraemic syndrome A stakeholder meeting was held on 24 June 2014 to discuss the Pharmaceutical Benefit